CVM
Price
$0.40
Change
-$0.00 (-0.00%)
Updated
Jan 17 closing price
Capitalization
29.84M
25 days until earnings call
MDGL
Price
$293.64
Change
+$20.85 (+7.64%)
Updated
Jan 17 closing price
Capitalization
6.4B
38 days until earnings call
Ad is loading...

CVM vs MDGL

Header iconCVM vs MDGL Comparison
Open Charts CVM vs MDGLBanner chart's image
Cel-Sci
Price$0.40
Change-$0.00 (-0.00%)
Volume$254.31K
Capitalization29.84M
Madrigal Pharmaceuticals
Price$293.64
Change+$20.85 (+7.64%)
Volume$866.12K
Capitalization6.4B
CVM vs MDGL Comparison Chart
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVM vs. MDGL commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and MDGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CVM: $0.40 vs. MDGL: $293.64)
Brand notoriety: CVM: Notable vs. MDGL: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 21% vs. MDGL: 221%
Market capitalization -- CVM: $29.84M vs. MDGL: $6.4B
CVM [@Biotechnology] is valued at $29.84M. MDGL’s [@Biotechnology] market capitalization is $6.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than CVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 3 bullish TA indicator(s).

  • CVM’s TA Score: 4 bullish, 4 bearish.
  • MDGL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CVM is a better buy in the short-term than MDGL.

Price Growth

CVM (@Biotechnology) experienced а -5.32% price change this week, while MDGL (@Biotechnology) price change was -13.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CVM is expected to report earnings on Feb 13, 2025.

MDGL is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.4B) has a higher market cap than CVM($29.8M). CVM YTD gains are higher at: 0.675 vs. MDGL (-4.838). CVM has higher annual earnings (EBITDA): -23.71M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. CVM (385K). CVM has less debt than MDGL: CVM (12.1M) vs MDGL (119M). MDGL has higher revenues than CVM: MDGL (76.8M) vs CVM (0).
CVMMDGLCVM / MDGL
Capitalization29.8M6.4B0%
EBITDA-23.71M-502.65M5%
Gain YTD0.675-4.838-14%
P/E RatioN/AN/A-
Revenue076.8M-
Total Cash385K999M0%
Total Debt12.1M119M10%
FUNDAMENTALS RATINGS
CVM vs MDGL: Fundamental Ratings
CVM
MDGL
OUTLOOK RATING
1..100
6232
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10030
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9742
P/E GROWTH RATING
1..100
56100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (68) in the Pharmaceuticals Other industry is in the same range as CVM (98) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CVM’s over the last 12 months.

MDGL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is significantly better than the same rating for CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CVM’s over the last 12 months.

MDGL's SMR Rating (99) in the Pharmaceuticals Other industry is in the same range as CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CVM’s over the last 12 months.

MDGL's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for CVM (97) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CVM’s over the last 12 months.

CVM's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CVM’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMMDGL
RSI
ODDS (%)
Bullish Trend 11 days ago
89%
Bearish Trend 11 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
90%
Momentum
ODDS (%)
Bearish Trend 11 days ago
88%
Bullish Trend 11 days ago
76%
MACD
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
76%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 19 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 11 days ago
85%
Bearish Trend 11 days ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
79%
View a ticker or compare two or three
Ad is loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XMMO129.690.58
+0.45%
Invesco S&P MidCap Momentum ETF
LGOV20.810.04
+0.19%
First Trust Long Duration Opp ETF
SIO25.460.04
+0.17%
Touchstone Strategic Income ETF
FLSW32.740.03
+0.09%
Franklin FTSE Switzerland ETF
JHDV35.26N/A
N/A
JHancock U.S. High Dividend ETF

CVM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CVM has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CVM jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVM
1D Price
Change %
CVM100%
+0.90%
MDGL - CVM
43%
Loosely correlated
+7.64%
CYTK - CVM
40%
Loosely correlated
-2.66%
ADXN - CVM
39%
Loosely correlated
+0.25%
EYPT - CVM
38%
Loosely correlated
+2.89%
ABP - CVM
32%
Poorly correlated
-3.70%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+7.64%
KANT - MDGL
62%
Loosely correlated
N/A
VXRT - MDGL
61%
Loosely correlated
-0.20%
ALXO - MDGL
56%
Loosely correlated
+6.75%
REPL - MDGL
55%
Loosely correlated
-2.12%
ZNTL - MDGL
51%
Loosely correlated
-6.28%
More